Trulicity

What is Trulicity?

Trulicity is a prescription injectable medication containing dulaglutide, a once-weekly GLP-1 receptor agonist manufactured by Eli Lilly and Company. The FDA approved Trulicity on September 18, 2014, under biologics license application number 125469 for adults with type 2 diabetes, making it Eli Lilly's first GLP-1 agonist and one of the first weekly GLP-1 products on the U.S. market. The label was expanded in February 2020 to include reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes, either with established cardiovascular disease or multiple cardiovascular risk factors — a broader cardiovascular indication than any other GLP-1 agonist at the time. Trulicity is administered as a once-weekly subcutaneous injection using a pre-filled, single-dose auto-injector at doses of 0.75 mg, 1.5 mg, 3 mg, or 4.5 mg. It has been a widely prescribed GLP-1 option for type 2 diabetes because of its simple auto-injector, broad cardiovascular label, and lower injection-site reaction rate than some alternatives.

How Trulicity works

Trulicity works by mimicking GLP-1, the natural incretin hormone released by the intestine after meals. Dulaglutide is a fusion protein: a modified GLP-1 analogue connected to a fragment of human immunoglobulin G4 (IgG4-Fc). This engineered structure resists degradation by the DPP-4 enzyme and has a half-life of approximately five days, supporting once-weekly dosing. When dulaglutide binds the GLP-1 receptor, it produces four coordinated effects: it stimulates glucose-dependent insulin secretion from pancreatic beta cells (only when blood sugar is elevated, which keeps hypoglycemia risk low), suppresses inappropriate glucagon release from alpha cells, slows gastric emptying so post-meal glucose rises more gradually, and reduces appetite through action on central nervous system pathways. The IgG4-Fc anchor gives Trulicity a somewhat slower onset of drug effect compared with Ozempic or Mounjaro, but produces steady exposure throughout the week and smooth clinical response. Steady-state plasma concentrations are reached after two to four weeks of weekly dosing.

Who Trulicity is for

Trulicity is FDA-approved for two patient populations with type 2 diabetes:

• Adults with type 2 diabetes — as an adjunct to diet and exercise to improve glycemic control.
• Adults with type 2 diabetes and cardiovascular risk — for reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have either established cardiovascular disease or multiple cardiovascular risk factors. This is a broader indication than Ozempic's or Victoza's CV indications, which both require established cardiovascular disease.

Your prescriber will evaluate current A1C and glycemic trajectory, kidney function, history of pancreatitis or gallbladder disease, any personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and insurance coverage. Trulicity is not FDA-approved for type 1 diabetes, weight management on its own, use during pregnancy or breastfeeding, or pediatric patients under 10. It is approved for pediatric type 2 diabetes patients aged 10 and older based on the AWARD-PEDS trial, making it one of the few GLP-1 options for pediatric type 2 diabetes.

How to take Trulicity

Trulicity is administered as a subcutaneous injection once weekly on the same day each week, at any time of day, with or without food. The injection site is the abdomen, thigh, or upper arm, rotating sites between doses. Trulicity's auto-injector is widely considered one of the most patient-friendly in the GLP-1 class — the needle is hidden, the device depresses automatically once pressed against the skin, and there is no need to pinch skin, mix medications, or prime the needle. Each auto-injector is single-use and discarded after use; never reuse or share.

The titration schedule starts at 0.75 mg once weekly for four weeks. This starter dose is effective for some patients who need modest A1C reduction, though most patients titrate up. After four weeks, the dose increases to 1.5 mg weekly, which is the most commonly used maintenance dose. If additional glycemic control is needed, the dose can be increased to 3 mg weekly after at least four weeks, and ultimately to 4.5 mg weekly (the maximum approved dose) after at least four weeks at 3 mg. Unlike some GLP-1 agents, Trulicity does not require a specific starter-only dose — the 0.75 mg dose can be used as a long-term maintenance dose for patients who achieve their glycemic targets without titrating higher.

If you miss a dose and the next scheduled dose is more than three days away, inject the missed dose as soon as you remember. If the next dose is less than three days away, skip the missed dose and resume your regular weekly schedule. Do not take two doses within a three-day window. Store unopened auto-injectors in the refrigerator between 36°F and 46°F (2-8°C). After removal from refrigeration, auto-injectors may be kept at room temperature (up to 86°F / 30°C) for up to 14 days before being discarded.

Side effects of Trulicity

Trulicity's side-effect profile is similar to other weekly GLP-1 agents, with gastrointestinal effects most prominent during titration and injection-site reactions less common than with some alternatives. All frequencies below come from the AWARD clinical trial program pooled data in the FDA prescribing information.

Common side effects (worst during titration, typically improving over 2 to 4 weeks):

• Nausea — reported in approximately 12 to 21 percent of patients depending on dose, peaking in the first weeks of a new dose
• Diarrhea — 8 to 13 percent
• Vomiting — 6 to 12 percent
• Abdominal pain — 6 to 9 percent
• Decreased appetite — welcome in most patients with concurrent overweight
• Dyspepsia (indigestion) — 4 to 6 percent
• Fatigue — 5 percent
• Injection site reactions — less than 1 percent, notably lower than Bydureon BCise

Less common but serious adverse events requiring prompt medical attention:

• Acute pancreatitis (less than 1 percent) — severe, persistent upper abdominal pain radiating to the back
• Gallbladder events (cholelithiasis, cholecystitis) — risk rises with any rapid weight loss
• Acute kidney injury — secondary to dehydration from persistent GI effects
• Hypoglycemia — uncommon with Trulicity alone; risk rises sharply when combined with insulin or sulfonylureas
• Diabetic retinopathy complications — rapid improvement in glycemia may temporarily worsen pre-existing retinopathy
• Serious allergic reactions — anaphylaxis and angioedema reported post-marketing

Management strategies — stay at a given dose longer before advancing if side effects are bothersome, eat smaller meals, avoid high-fat or very spicy foods during the first weeks at each new dose, stay well hydrated, and limit alcohol. Contact your prescriber for severe abdominal pain, persistent vomiting, signs of dehydration, vision changes, or any rapid new symptom.

Who should not take Trulicity

Trulicity is contraindicated for patients with any of the following:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to dulaglutide or any component of the formulation
• Severe gastrointestinal disease including gastroparesis

Boxed warning: Dulaglutide caused thyroid C-cell tumors, including medullary thyroid carcinoma, in rodent studies. Whether this risk extends to humans is unknown. Patients should be counseled to report any persistent neck mass, difficulty swallowing, shortness of breath, or unexplained hoarseness to their prescriber.

Additional caution is appropriate for patients with a history of pancreatitis, severe gastrointestinal motility disorders, kidney impairment (dehydration from GI effects can worsen renal function), pre-existing diabetic retinopathy, pregnancy or plans to become pregnant, or breastfeeding. Because Trulicity slows gastric emptying, the absorption of orally administered medications may be delayed — review oral contraceptives, thyroid hormone, warfarin, and time-critical cardiovascular drugs with your pharmacist. Patients taking insulin or a sulfonylurea may need dose reductions when Trulicity is added. Concurrent use with other GLP-1 receptor agonists (Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Victoza, Saxenda, Byetta, Bydureon, Foundayo) is not recommended.

What to expect on Trulicity

The Trulicity experience is shaped by its smooth, gradual onset and relatively mild side-effect profile compared with some alternatives.

Week 1 to week 4 (0.75 mg starter dose). Unlike some GLP-1 agents, Trulicity's 0.75 mg starter dose is therapeutically active. A1C typically begins to improve within the first two to three weeks. Some patients see adequate glycemic control at 0.75 mg and stay on this dose long-term. Side effects are typically mild during this period.

Month 2 to month 3 (1.5 mg maintenance). Most patients advance to the 1.5 mg dose. Mean A1C reduction at 26 weeks on 1.5 mg in the AWARD trial program was approximately 1.1 to 1.5 percentage points from baseline. Weight loss averages 2 to 3 kg — modest compared with semaglutide or tirzepatide-based agents. GI side effects typically settle as the body adapts.

Month 3 to month 6 (3 mg or 4.5 mg if needed). Patients who need additional A1C reduction may titrate up. The 3 mg and 4.5 mg doses produce incrementally greater A1C reduction (approximately 1.6 and 1.8 percentage points, respectively, in the AWARD-11 trial) with modestly increased GI side effects. Most patients remain on 1.5 mg as the preferred maintenance dose.

Beyond 6 months. Patients who continue Trulicity generally sustain their glycemic and weight improvements. The REWIND cardiovascular outcomes trial followed patients for a median of 5.4 years and showed a 12 percent reduction in major adverse cardiovascular events over time. Your prescriber will schedule follow-up every three to six months to monitor A1C, weight, kidney function, cardiovascular risk markers, and any emerging side effects. Stopping Trulicity typically reverses much of the glycemic improvement and modest weight loss within six months.

Trulicity cost and coverage

The list price of Trulicity is approximately $979 per four-auto-injector pack (one month of therapy at any dose) before insurance, based on the Eli Lilly wholesale acquisition cost. There is no FDA-approved generic version, and Lilly holds patent protection blocking generic competition for several more years.

What you actually pay depends heavily on coverage:

• Commercial insurance (Type 2 diabetes): Most major plans cover Trulicity for patients with confirmed type 2 diabetes, typically with prior authorization. Copays commonly range from $25 to $100 per month on preferred tiers. Trulicity has historically been on broad preferred formulary positions because of its simple auto-injector and early market entry.
• Medicare Part D: Covers Trulicity for type 2 diabetes. The Inflation Reduction Act caps total annual out-of-pocket prescription spending at $2,000 for Part D beneficiaries starting in 2025.
• Medicaid: Generally covers Trulicity for type 2 diabetes, with prior-authorization rules varying by state.
• Manufacturer savings: The Lilly Trulicity Savings Card can reduce eligible commercially-insured patients' copay to as low as $25 per month for up to 12 prescriptions; not available to Medicare or Medicaid beneficiaries.
• Patient assistance: Lilly Cares Foundation Patient Assistance Program may provide Trulicity at reduced or no cost to uninsured patients meeting income criteria.
• LillyDirect: Eli Lilly's direct-to-consumer pharmacy offers simplified ordering and potential self-pay pricing for certain doses.

Check your specific plan's coverage and the current Lilly savings program before filling — formulary placement and savings terms change periodically as the GLP-1 landscape evolves.